Protalix BioTherapeutics, Inc. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Protalix reported H1 2026 net income of $22.1M ($0.28 basic EPS) vs. $3.5M loss prior year, driven by $27.2M product revenues (up $1.8M YoY) and a $25.0M Chiesi milestone payment received in Q1 2026 for Elfabrio E4W EU approval. Total H1 revenue reached $53.6M vs. $25.8M prior year. The company reaffirmed full-year 2026 total revenue guidance of $78–$83M (including the Chiesi milestone), with product-only revenues of $33–35M for Elfabrio and $20–23M for Elelyso. Cash stood at $40.7M (vs. $14.7M end-2025); no debt. PRX-115 Phase 2 RELEASE trial enrollment continues; top-line data expected H2 2027.
Why this rating
Company swung to profitability and doubled YoY revenue, but near-term growth dependent on one $25M non-recurring milestone and partner (Chiesi) execution. Relative to $113M market cap, H1 net income is material (~20% annual run-rate), yet guidance driven by milestone already received. Modest product growth (+$1.8M) and clinical progress offset by revenue visibility tied to partnership.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.